L 751788
Latest Information Update: 10 Nov 2000
Price :
$50 *
At a glance
- Originator Merck & Co
- Class Antiacnes
- Mechanism of Action Cholestenone 5 alpha-reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Acne
Most Recent Events
- 10 Nov 2000 No-Development-Reported for Acne in USA (Unknown route)
- 20 Feb 1997 New profile
- 20 Feb 1997 Preclinical development for Acne in USA (Unknown route)